

A Study of AT2101 (Afeostat Tartrate) in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement Therapy

San Francisco, California, United States

Coral Springs, Florida, United States

Decatur, Georgia, United States

Iowa City, Iowa, United States

New York, New York, United States

Cincinnati, Ohio, United States

Portland, Oregon, United States

Philadelphia, Pennsylvania, United States

Pittsburgh, Pennsylvania, United States

Houston, Texas, United States

This study was conducted to test the safety and tolerability of afeostat tartrate in participants with type 1 Gaucher disease already receiving enzyme replacement therapy.